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Abstract
Background: The proliferating cell nuclear antigen (PCNA) is an essential component of DNA replication, cell cycle
regulation, and epigenetic inheritance. High expression of PCNA is associated with poor prognosis in patients with breast
cancer. The 59-region of the PCNA gene contains two computationally-detected estrogen response element (ERE)
sequences, one of which is evolutionarily conserved. Both of these sequences are of undocumented cis-regulatory function.
We recently demonstrated that estradiol (E2) enhances PCNA mRNA expression in MCF7 breast cancer cells. MCF7 cells
proliferate in response to E2.
Methodology/Principal Findings: Here, we demonstrate that E2 rapidly enhanced PCNA mRNA and protein expression in a
process that requires ERa as well as de novo protein synthesis. One of the two upstream ERE sequences was specifically
bound by ERa-containing protein complexes, in vitro, in gel shift analysis. Yet, each ERE sequence, when cloned as a single
copy, or when engineered as two tandem copies of the ERE-containing sequence, was not capable of activating a luciferase
reporter construct in response to E2. In MCF7 cells, neither ERE-containing genomic region demonstrated E2-dependent
recruitment of ERa by sensitive ChIP-PCR assays.
Conclusion/Significance: We conclude that E2 enhances PCNA gene expression by an indirect process and that
computational detection of EREs, even when evolutionarily conserved and when near E2-responsive genes, requires
biochemical validation.
Citation: Wang C, Yu J, Kallen CB (2008) Two Estrogen Response Element Sequences Near the PCNA Gene Are Not Responsible for Its Estrogen-Enhanced
Expression in MCF7 Cells. PLoS ONE 3(10): e3523. doi:10.1371/journal.pone.0003523
Editor: Laszlo Tora, Institute of Genetics and Molecular and Cellular Biology, France
Received July 15, 2008; Accepted October 6, 2008; Published October 24, 2008
Copyright:  2008 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CBK is supported by a grant from the Research Scientist Development Program (NIH-5K12HD00849) and by the Society for Gynecologic Investigation.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: caleb.kallen@emory.edu
Introduction
The proliferating cell nuclear antigen (PCNA) gene product is a
nuclear protein that acts as a cofactor for DNA polymerase-d and
participates in DNA synthesis [1] and repair [2](for reviews see
[3,4]). In addition, by interacting with a wide array of proteins,
PCNA serves essential functions in cell cycle progression [5],
epigenetic inheritance [6,7], and gene transcription [8,9]. PCNA
gene expression is generally low in quiescent cells, increases with
cell proliferation [10], and is tightly controlled within the cell cycle.
In response to proliferative stimuli, PCNA mRNA and protein
levels both increase during the G1/S transition, commensurate the
protein’s role in DNA replication [11–14].
PCNA synthesis is induced by diverse stimuli in a cell-type
specific fashion, including: EGF, PDGF, and serum in 3T3 cells
[15,16], interleukin 2 (IL-2) in T-lymphocytes [17], and p53 [18]
and adenovirus infection in HeLa cells [19]. There appear to be
transcriptional and post-transcriptional mechanisms for regulating
PCNA mRNA levels in 3T3 cells by processes that are not fully
characterized [10,17,20,21]. No formal study of PCNA gene
regulation has been demonstrated in breast cancer cells.
Most studies have observed that high PCNA gene expression
correlates with increased metastatic potential and decreased
survival in patients with breast carcinoma [22–28]. Many breast
and uterine cancers depend upon E2 for neoplastic initiation,
development, or metastasis, and antiestrogen therapies remain the
mainstay of treatment and prevention for ERa-expressing breast
cancers. The E2 response in breast cancer cells is predominantly
mediated by ERa, a ligand-activated transcription factor [29].
We confirmed that PCNA gene expression is enhanced by E2
exposure in MCF7 breast cancer cells which express ERa and
proliferate in response to E2 [30,31]. We, and others, have
detected two putative estrogen response elements (EREs) in the 59
region of the PCNA gene, one of which is conserved between
murine and human species, and both of which may serve as cis-
regulatory elements for ERa-mediated gene regulation [32].
Recently, PCNA was shown to physically interact with ERa
[33] and RARa [34] and to modulate gene transcription regulated
by these transcription factors. These observations raise the
possibility that E2-stimulated ERa activates PCNA gene expres-
sion, leading to feedback regulation of ERa transcriptional
functions by ERa-bound PCNA. The process of PCNA gene
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some ERa-expressing cancers.
The PCNA promoter is regulated at the transcriptional level by
many transcription factors including E1A [35,36], ATF1 [37],
RFX1 [38], CBP [39], p107 [40], p53 [18,19,41], and E2F
[11,12]. In some systems, basal transcription is augmented at G1/
S by inducible regulatory elements [12]. No role for ERa has been
demonstrated in the regulation of PCNA gene expression although
estrogens act as potent mitogens in both normal and neoplastic
breast and uterine tissues. Because eukaryotic cis-regulatory
elements may reside great genomic distances from target genes
[31,42–45], and because the putative EREs that we identified are
located 1,200–10,000 bp from either transcription start site (TSS)
demonstrated for PCNA, we thought it important to test these
elements for functional significance. Our goals were to understand
the predictive value of computational ERE detection for an E2-
responsive gene and to better define the mechanisms by which
estrogen stimulates PCNA gene expression in breast cancer cells.
Our data indicate that E2 enhances PCNA gene expression by an
indirect process and that computational detection of EREs, even
when evolutionarily conserved and when near E2-responsive
genes, requires biochemical validation.
Results
E2 stimulated PCNA mRNA and protein expression in a
process that requires de novo protein synthesis
We recently reported the results of microarray-based gene
expression profiling using the MCF7 breast cancer cell line, a
model system for E2-dependent breast tumors [31]. MCF7 cells
express ERa and proliferate in response to E2 exposure. We
observed increased PCNA gene expression after 4, 12, and
24 hours of E2 exposure. Notably, two putative EREs were
previously detected upstream of PCNA by Bourdeau et al, who
applied large scale computational analyses to the human and
mouse genomes for detection of conserved ERE sequences [32].
Our analysis revealed that the both ERE sequences are 100%
conserved between Rhesus and human, whereas the 39-ERE
sequence also shares 79% identity with mouse, indicating that the
39-ERE is more evolutionarily conserved. These ERE sequences
were never tested for function.
Quantitative reverse transcription polymerase chain reaction
(Q-RT-PCR) was applied to MCF7 cell lysates and confirmed
greater than 2-fold induction of PCNA mRNA after six hours E2
exposure (Figure 1A). Known E2-responsive genes also tested
include TFF1, MYC, STC2, and DCC1. Similar changes in PCNA
protein levels were observed after E2 treatment of MCF7 cells
(Figure 1B). The E2-stimulated expression of PCNA mRNA was
sensitive to co-treatment with the protein synthesis inhibitor
cycloheximide (CHX), suggesting a secondary, or indirect,
transcriptional effect of E2 exposure (Figure 1A). Interestingly,
DCC1, a component of the replication factor C (RFC) which loads
PCNA onto DNA during DNA replication, demonstrated
expression that was similarly E2 responsive and CHX sensitive.
These data are consistent with a model in which DNA replication
is regulated within the cell cycle, in part, by the regulated synthesis
and degradation of the replicative machinery [46].
There exist direct transcriptional targets of ERa that require de
novo protein synthesis in order to be transcriptionally regulated by
the receptor. For example, the ERa gene target c-fos is rapidly
Figure 1. Estrogen stimulates PCNA mRNA and protein expression in MCF7 cells. (A) MCF7 cells were treated for six hours with or without
E2 (100 nM) and with or without CHX (25 mg/ml), an inhibitor of protein synthesis. RNA was collected and subjected to Q-RT-PCR. Known E2-
responsive genes included TFF1, MYC, STC2, and DCC1. The E2-stimulated expression of PCNA and DCC1 was lost when cells were co-treated CHX.
Values are the average of three experiments, performed in triplicate, with SEM indicated. (B) PCNA protein levels were measured from MCF7 cell
lysates by Western blot after 0, and 24 hours of E2 (10 nM) exposure. Results using ACTIN-specific antibody on the same lysates are also shown. The
data are representative of an experiment performed twice. * P , 0.02 comparing control with E2-treated.
doi:10.1371/journal.pone.0003523.g001
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synthesis is required in order to produce a sustained c-fos
transcriptional response to E2 in MCF7 cells [49]. Similarly,
there exist gene targets that are repressed by ERa only after
induction of the corepressor protein NRIP-1 [44]. Thus, the fact
that the PCNA response to E2 was CHX-sensitive did not preclude
the gene from being a direct responder to ERa.
E2-enhanced PCNA gene expression was blocked by
inhibition of ERa function
Blocking an E2-mediated transcriptional response by co-
treatment with ICI 182,780, a pure ERa antagonist, indicates
that the observed effect is mediated by ERa [50,51]. In MCF7
cells, the E2-stimulated expression of PCNA was blocked by co-
treatment with ICI 182,170 and by inhibition of gene transcription
using actinomycin D (ActD) (Figure 2). Similar results were
observed for MYC gene expression, which is also E2-responsive
and a direct gene target of ERa [52]. These data support the
hypothesis that E2-stimulated PCNA gene expression requires both
the activity of ERa and de novo gene transcription.
We recently demonstrated that siRNA-mediated knockdown of
PCNA gene expression greatly inhibited E2-stimulated cell
proliferation in MCF7 cells [31]. These data supported the
hypothesis that PCNA is an important mediator of E2-stimulated
cell proliferation in MCF7 cells. Our analysis of the PCNA gene
locus confirmed two imperfect ERE’s within 10 Kb of the two
TSSs described for the gene (Figure 3A) [12,17]. Each putative
ERE (herein dubbed PCNA-ERE1 and PCNA-ERE2) demon-
strates a single nucleotide mismatch from the core 13 bp consensus
(or ‘‘canonical’’) ERE sequence. Notably, the majority of EREs
identified and validated in the human genome do not demonstrate
perfect consensus sequences, indicating a high degree of
heterogeneity for functional ERE sequences [53–57]. Similarly,
the mere presence of an ERE-like sequence is not sufficient to
ensure ERa binding or ERa-mediated transcriptional responses in
the majority of chromatin contexts [31,58]. These observations
indicate that ERE sequences must combine with additional factors
in order to function. Such factors may include regional histone
composition, distribution, and post-translational histone modifica-
tions, DNA methylation status, and regional DNA sequences (with
associated trans-factors) that create a transcriptionally permissive
environment for activated ERa [59].
A predicted ERE sequence near the PCNA gene was
capable of binding to ERa in vitro
We performed electrophoretic mobility shift assays (EMSA)
using the radiolabeled PCNA-ERE1 sequence with recombinant
ERa protein. In order to promote receptor-DNA binding, and to
control for the presence or absence of ERa protein, recombinant
ERa was combined with cofactors present in nuclear extracts from
an ERa-negative, immortalized human endometrial stromal cell
(HESC) line [60]. ERa-containing protein complexes were shown
to bind to PCNA-ERE1, in vitro, as evidenced by supershift with an
antibody specific for ERa (Figure 3B). No estrogen receptor-
containing complex was noted from HESC cell extracts alone (not
shown). No supershift was noted using antibodies targeting the
transcription factors Sp1, AP-1 or ARP-1/COUP-TF2, although
these factors have been demonstrated to bind with ERa at selected
promoters (Figure 3C) [61–63]. Binding was weaker for PCNA-
ERE1 than that observed for a consensus ERE sequence
(Figure 3B) but stronger than that observed with PCNA-ERE2,
for which binding was weakly detectable (not shown).
ERa-dependent binding to radiolabeled PCNA-ERE1 could be
competed away using excess unlabeled (‘‘cold’’) PCNA-ERE1
probe (P-ERE1) whereas a similar probe with mutations in the two
half-sites of the ERE (P-ERE1mut) did not efficiently compete for
labeled PCNA-ERE1-bound receptor (Figure 3C). These data
suggested that one or both of these putative EREs might represent
ERa-responsive cis-regulatory elements that modulate PCNA gene
expression in MCF7 cells. It is recognized that the affinity of
receptor binding to an ERE, as measured in vitro, need not
correlate with the potency of the enhancer function that is
observed [53] and that multiple EREs can work cooperatively in
order to enhance target gene transcription [64,65].
Figure 2. Estrogen-stimulated PCNA gene expression requires ERa and de novo gene transcription. MCF7 cells were treated with or
without E2 (100 nM) for 6 hours. Additional treatments included ActD (2 mg/ml), an inhibitor of gene transcription, and ICI 182,780 (1 mM), a pure
estrogen receptor antagonist. RNA was collected and subjected to Q-RT-PCR. PCNA mRNA levels were compared with MYC mRNA levels from the
same samples. Values are the average of three experiments, performed in triplicate, with SEM indicated. * P , 0.05 comparing control with E2-
treated.
doi:10.1371/journal.pone.0003523.g002
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reporter expression in response to E2 treatment
We cloned genomic fragments corresponding to each PCNA-
ERE into luciferase reporter constructs and tested these for
enhancer function, in vitro. Surprisingly, neither an 822 bp
fragment containing PCNA-ERE1 nor a 551 bp fragment
containing PCNA-ERE2 demonstrated E2-inducible enhancer
function in MCF7 cells (Figure 4). Similar results were obtained
when these constructs were tested with co-expressed ERa in
HESC cells (which do not express endogenous ERa but respond to
E2 when made to express ERa (not shown)). Thus, changing the
cell type in which we tested the reporter constructs, and
presumably the cohort of available transcription factor co-
regulatory proteins within the cell nucleus [66], failed to indicate
enhancer function for the putative ERE sequences being tested.
Luciferase reporter assays that use single copy response elements
are sometimes weakly responsive to transcription factors. Further,
the function of any cloned enhancer region may be subject to
inhibition by neighboring cis-a n dtrans-regulatory elements,
depending upon the length of DNA that is cloned and the inclusion
or exclusion of such regulatory elements in the reporter construct.
This phenomenon could produce false-negative observations in
luciferasereporter assaysthatwoulddepend,inpart, upon thesizeof
the genomic fragment that is employed in the assay. It is, therefore,
common to assay multiple tandem copies of cis-regulatory elements
in order to demonstrate enhancer function, in vitro.
We engineered luciferase reporter constructs with two tandem
copies of the 15 bp PCNA-ERE1 sequence or two copies of the
PCNA-ERE2 sequence (26PCNA-ERE1 and 26PCNA-ERE2),
to test these isolated sequences for enhancer activity. As seen with
Figure 3. Two EREs reside near the TSSs for PCNA, one binds to ERa in vitro. (A) Genomic sequences of two EREs, the 59-ERE (PCNA-ERE1) and
the 39-ERE (PCNA-ERE2), are indicated, with associated distances from the 39 transcription start site (TSS) of the PCNA gene. Deviations from the
consensus ERE sequence are indicated in lower case. Previously-described regulatory regions are similarly indicated (see main text). (B) EMSA was
performed using HESC cell nuclear lysates plus recombinant ERa (rERa) and radiolabeled consensus ERE or PCNA-ERE1 probes. The ERa-containing
complex (arrow) is demonstrated by supershift (arrowhead) using a monoclonal antibody that recognizes ERa. In the middle lane, ‘‘PO’’ indicates
probe only, and lacks proteins. (C) EMSA data as in (B), wherein supershift is noted using antibody specific for ERa but not when using antibodies for
ERa tethering partners Sp1, c-Jun (a member of AP1 complexes), or ARP1/COUP-TFII. ERa-containing radioactive complexes are efficiently competed
away by unlabeled (‘‘cold’’) wild-type PCNA-ERE1 sequences (P-ERE1) but not with cold probe sequences mutated at the ERE-containing residues (P-
ERE1-mut).
doi:10.1371/journal.pone.0003523.g003
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sequences did not demonstrate E2-responsive enhancer function in
MCF7 cells (Figure 4). When each tandem ERE sequence was
mutated by one nucleotide to conform to a perfect 13 bp consensus
ERE (D-26PCNA-ERE1 and D-26PCNA-ERE2), strong E2-
responsive enhancer function was observed (Figure 4). These results
confirmed that the promoter-reporter construct, pGL2-promoter, is
functional in response to E2 in MCF7 cells when harboring bona fide
ERE enhancer sequences. Taken together, these data did not
supportthe hypothesisthat theputative EREs, each computationally
detected, are likely to function as ERa-regulated enhancer elements
for the PCNA gene in MCF7 cells.
Two ERE sequences near the PCNA gene were not bound
by ERa in vivo
In light of the fact that the ERE-like sequences near PCNA are
nearly consensus EREs, and that PCNA gene expression is E2-
responsive, we wondered whether the in vitro assays that we
employed to detect enhancer function could have produced
spurious results. It remained possible that the chromatin context,
in vivo, might dictate enhancer function in ways not observed using
plasmid DNA in reporter assays. Imperfect (i.e. non-consensus)
EREs have been demonstrated to have function when optimally
positioned with regards to target TSSs, wherein they can provide
sufficient affinity for ERa binding, permit important DNA
bending, and favor specific patterns of coregulator recruitment
to the target gene promoter [67–69].
Although we were unable to detect ERa binding to PCNA-
ERE1 or PCNA-ERE2 using ChIP-on-chip in response to E2
[31], we reasoned that this result could reflect established
limitations in the sensitivity of this microarray-based approach.
When we compared our findings to other reports of genome-wide
location analysis for ERa in MCF7 cells, we similarly found no
evidence for recruitment of ERa to the PCNA gene locus using
ChIP-on-chip or alternative genomic approaches such as ChIP-
DSL and ChIP-PET [44,70,71]. Notably, the receptor location
analysis work in these studies compared ERa target occupancy
after chromatin immunoprecipitation using E2-treated cells
relative to ERa occupancy of chromatin DNA prepared from
cells not subjected to immunoprecipitation (i.e. sheared input). As
such, the approaches were not optimally designed to detect
changes in target occupancy that depend upon E2 exposure,
which can be tested by comparing ChIP of untreated cells (vehicle-
treated ChIP) with ChIP from E2-treated cells.
Inorder to testfor E2-dependent binding ofERa toPCNA-ERE1
or PCNA-ERE2, we performed ChIP-PCR using primers that span
each putative ERE. Using ChIP-PCR, we were unable to
demonstrate recruitment of ERa to either putative ERE in response
to E2 (Figure 5). Similar results were obtained using multiple
alternative PCR primer pairs targeting the same genomic regions
(not shown). In toto, more than 3 primer pairs were used to evaluate
ERa occupancy at each putative cis-element in response to E2; all
demonstrated no evidence for receptor recruitment to the ERE
sequences in response to hormone. The ChIP-PCR data shown in
Figure 5 included a 45 min exposure to E2, a treatment that has
been demonstrated to produce optimal ERa recruitment to target
enhancers [72]. We obtained identical results with E2 treatments
extended for 3 and 6 hours prior to protein crosslinking (not shown).
A genomic locus (chr7:72384008-72385027) that lacks an ERE
and that failed to be detected using ChIP-on-chip (dubbed ERE-
neg) also failed to be enriched for ERa using ChIP-PCR when
comparing control and E2-treated cells (Figure 5). By contrast,
ChIP-PCR confirmed E2-dependent recruitment of ERa to
several known genomic targets including TFF1, MYC, GREB1,
and CTSD. In addition, ChIP-PCR confirmed E2-dependent
recruitment of ERa to four targets that we previously identified
using ChIP-on-chip [31], dubbed I20, J23, D54, and F15 (see
methods for genomic locations) (Figure 5). These data suggest that
neither of the putative EREs detected near PCNA binds to ERa in
an E2-dependent fashion, in vivo, in MCF7 cells. Further, the data
demonstrate a good correlation between our ChIP-on-chip
datasets and ChIP-PCR datasets.
Figure 4. Two EREs near PCNA do not enhance expression of a reporter in response to estrogen. The 822 bp genomic fragment
containing PCNA-ERE1 and the 551 bp genomic fragment containing PCNA-ERE2 do not enhance luciferase reporter activity in response to E2. Two
tandem copies of the isolated 15 bp ERE sequence found within PCNA-ERE1 (26PCNA-ERE1) or PCNA-ERE2 (26PCNA-ERE2) did not enhance reporter
activity in response to E2. When these tandem ERE sequences were mutated to produce perfect 13 bp core consensus ERE sequences (D-26PCNA-
ERE1 and D-26PCNA-ERE2) they produced E2-dependent enhancement of reporter activity in MCF7 cells. Values are the average of three
experiments, performed in triplicate, with SEM indicated. * P , 0.002 comparing E2-treated with control.
doi:10.1371/journal.pone.0003523.g004
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Our data show that PCNA, an essential participant in DNA
replication, epigenetic programming, and a regulator of the cell
cycle, is up-regulated by E2 exposure in MCF7 cells. Epigenetic
alterations play critical roles in tumorigenesis and cancer
progression [73,74] and we recently demonstrated that high
protein expression of the E2-responsive histone variant H2A.Z in
primary breast tumors correlates with decreased patient survival
[31]. It is attractive to consider, and previously has been postulated
[30,33], that the E2-dependent expression of PCNA is potentially
important for the proliferation of a diversity of tissues and tumors.
Nair and colleagues recently reported an ERa-dependent
proliferative effect in which estrogen enhanced PCNA gene
expression in cancers of the cervix but not in normal cervix
[75]. E2 exposure is a well-recognized risk factor for cancer of the
breast and endometrium, and E2 enhances PCNA gene expression
in human myometrial and leiomyoma tissues as well [76]. Most-
recently, E2-responsive tumor progression has been suggested for
epithelial ovarian cancer [77].
Our data indicate that, inMCF7cells, the E2 effect depends upon
new gene transcription and translation and is blocked by the pure
ERa-antagonist ICI 182,780. Although excellent computational
analysis [32], and preliminary in vitro data (EMSA), suggested that
the mechanism of PCNA gene regulation might include the function
of ERE sequences in the 59 region of the gene, our testing of the
most-likely sequence elements, using several approaches, failed to
confirm cis-regulatory function in MCF7 cells.
That a subset of ERa target genes may require the synthesis of
additional cofactor(s) prior to becoming subject to receptor-mediated
transcriptional regulation remained a possibility consistent with our
preliminary gene expression data. Such a model has been observed
for ERa gene targets that are repressed by ERa only after the
induction of corepressor protein NRIP-1 [44]. Similarly, some genes
targeted by ERa require the function of a chromatin modifier,
FOXA1, prior to becoming subject to ERa-mediated transactivation
[59,78]. The observation that E2 engenders gene regulatory cascades
that can be divided into temporal categories (i.e. immediate, early,
and late responses) is well-demonstrated [30,31]. These data indicate
that some genes are poised for immediate regulation, others may
represent downstream/indirect targets of ERa function, and still
other gene targets may require the synthesis of cofactors to modify
chromatintargetsinpreparationfor thearrivalofactivated ERa[78].
Neither the timing of a transcriptional response (early vs. late) nor the
sensitivity of the response to CHX can be taken as formal proof that a
given response is direct (i.e. ERa-mediated) or indirect.
This report describes two ERE-like sequences upstream of an
E2-responsive gene. Both sequences failed to demonstrate
transcriptional regulatory function in vitro and in vivo in MCF7
cells. PCNA-ERE1 resides within a repetitive element (Alu-Sc)
while PCNA-ERE2 does not. A single report described a
functional Alu-ERE for the BRCA1 gene [79] which, on further
inspection, was determined to be non-functional in MCF7 cells
[80]. The reported ERE sequence in those studies is not the same
as noted for PCNA-ERE1. Our results indicate that PCNA is
regulated in response to E2 either indirectly, or via a cis-acting
ERE not detected by several independent genome-wide location
analyses for ERa [31,44,70,71], and only after the synthesis of
newly translated protein(s). Importantly, in addition to ChIP-on-
chip approaches, two genome-wide location analyses utilized
ChIP-PET and the sensitive ChIP-DSL approaches; all demon-
strated no evidence for ERa recruitment to PCNA.
Five members of the E2F family of transcription factors (of which
humans have at least eight) are up-regulated by E2 in MCF7 cells
although direct transcriptional regulation by ERa remains to be
establishedforthesegenes[31].RecentdatasuggeststhatE2Ffamily
members are capable of binding to identical sequences as
homodimers or heterodimers (with DP family members) and may
often subserve redundant functions [81]. Increasing data indicate
Figure 5. ERa is not recruited to genomic PCNA-ERE1 or PCNA-ERE2, in vivo, after E2 exposure. MCF-7 cells were treated with or without
E2 for 45 minutes, then ChIP was performed using antibodies against ERa. Quantitative PCR using genomic primers residing within 500 bp of the
putative ERE sequences revealed no evidence that ERa is recruited to either putative ERE in response to E2 exposure. E2-stimulated ERa similarly
failed to be enriched at an ERE-less locus (ERE-neg) that was also negative in prior ChIP-on-chip studies. Similar studies using genomic PCR primers for
the E2-responsive genes TFF1, MYC, GREB1, and CTSD demonstrated rapid recruitment of ERa to these enhancer regions in response to E2. Also
shown is ChIP-PCR validation of ERa-bound loci detected using ChIP-on-chip, as previously reported [31], targeting loci I20, J23, D54, and F15 (see
methods section). Values are the average of three experiments, with SEM indicated. * P , 0.1 comparing E2-treated with control. ** P , 0.05
comparing E2-treated with control.
doi:10.1371/journal.pone.0003523.g005
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proliferation of breast cancer cells [82,83]. E2F1 regulates PCNA
gene expression in some systems [84]. We tested E2F1 using ChIP-
PCR and found no evidence for E2-dependent recruitment of E2F1
to the transcription start sites of the PCNA gene (data not shown).
Similar negative results were obtained when performing ChIP-PCR
using antibodies for Sp1 or AP-1 in order to interrogate both PCNA
ERE-likesequencesandthe twoTSSsofthePCNAgene(notshown).
ATF1 [37] and CREB1 are also regulators of PCNA gene expression
but were not enriched at the PCNA promoter in MCF7 cells in
genome-wide ChIP-chip analyses (S. Hua and K. White, manuscript
in preparation).
In order to identify alternative candidates that might mediate the
estrogen response of PCNA in MCF7 cells, we undertook a
computational analysis of predicted transcription factor binding
sites in the two promoter regions for PCNA. These data were then
correlated with gene expression data from our work, and from the
work of others, cataloging estrogen-responsive transcription factors
in MCF7 cells. The intersection of these datasets provides a list of
estrogen-responsive transcription factors with high-confidence
binding sites residing within two kilobases of each transcription start
site for the PCNA gene (Table S2). In addition to E2F family
members that warrant investigation (above), we have identified c/
EBPb, FOXC1, FOXJ2, GATA-3, POU2F1/AP-2c,R A R A ,
TFAP2C, and TFE3 as estrogen-responsive transcription factors
with predicted binding sites in one or both promoter regions of the
PCNA gene. Taken together, these data reveal good candidates for
the mediator of the estrogenic cascade leading to enhanced PCNA
gene expression in MCF7 cells. These candidates will be pursued in
our future studies.
Notably, ,2310 perfect 13 bp consensus EREs (GGTCAnnnT-
GACC) exist within the human genome. Permitting just one
nucleotide mismatch from the consensus sequence reveals nearly
50,000 ERE-like sites throughout the human genome. Our ChIP-
on-chip data, supported by biological plausibility, suggest that the
overwhelming majority of these sites are not functional in any given
cell type. Two groups have used MCF7 cells to perform whole
genome ChIP-on-chip for ERa location analysis, revealing between
,1600–3700 receptor-bound loci in response to E2 (with consid-
erable reproducibility) [31,44]. Analysis of the highest-confidence
ChIP sites,the1017 sites that are common toboth datasets,indicates
that more than 90% of the ERE-like sequences at these loci are not
perfect consensus sequences. Further, these datasets indicate that,
most likely, ,5–10% of perfect consensus ERE sites in the genome
are ERa-bound in response to E2 in MCF7 cells.
The chromatin and cellular determinants of ERa binding to
enhancer elements remain to be fully established. This issue raises
a cautionary note when drawing conclusions based upon
computational analyses of genomic sequence which, even when
evolutionarily conserved, will present hypotheses that must be
validated by formal molecular biological testing. We conclude that
computational detection of cis-regulatory elements in the human
genome, even when accompanied by appropriate gene expression
data, cannot be taken as proof of cis-regulatory element function in
vivo [32,85–87]. Each element must be tested, preferably using in
vivo assays such as ChIP-PCR and chromatin conformation
capture, in order to confirm cis-element function in any given
cell type and cell context.
Materials and Methods
Cell Culture
MCF7 cells (ATCC) were grown as described [78]. Cells were
changed to estrogen-depleted, phenol-free media consisting of
MEM alpha (Gibco) with 10% charcoal/dextran-stripped calf
serum, insulin (4 mg/ml, Sigma), penicillin G, streptomycin, and
L-glutamine (all Gibco), for 72 hours prior to treatments. Where
indicated, treatments included vehicle control (100% EtOH),
estradiol (10 nM or 100 nM, Sigma), actinomycin D (ActD, 2 mg/
mL, Sigma), cycloheximide (CHX, 25 mg/mL, Sigma), and ICI
182,780 (1 mM, Tocris Biosciences). Telomerase-immortalized
Human Endometrial Stromal Cells (HESC cells), a generous gift
from Dr. Graciela Krikun, were grown in the same media used for
the MCF7 cells. HESC cells have normal chromosome numbers
and structures [60].
Preparation of Nuclear Extracts and EMSA
HESC nuclear extracts (NE) were purified using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce) according
to the manufacturer’s instructions. HESC cells have no demon-
strable ERa activity using sensitive luciferase reporter assays and
no ERa protein detected by Western blot analysis (data not
shown). However, HESC cell nuclei have cofactors that promote
the binding of recombinant ERa to target DNA in EMSA and
these factors enhance binding when compared to recombinant
ERa alone (rERa, Affinity Bioreagents). EMSA experiments were
therefore conducted using HESC nuclear extracts combined with
rERa. Protein determinations were performed using the Micro
BCA assay (Pierce) and 5 mg of nuclear extract (with protease
inhibitors, Roche) plus rERa (170 nM) was used in each lane of a
5% acrylamide gel in TBE buffer. Oligonucleotide probes were
32P-labeled using T4 Polynucleotide Kinase 59 End Label System
(Promega) and purified using Mini Quick Spin Oligo Columns
(Roche). Each radiolabeled probe was used at ,200,000 cpm/lane
and binding reactions included Tris-HCl pH 8.0 (25mM), KCl
(50 mM), MgCl2 (6.25 mM), Glycerol (10%), DTT (0.5 mM) plus
relevant antibody where indicated (400 ng/reaction): anti-ERa
Ab-10 (LabVision), anti-cJun(N) sc-45 (Santa Cruz), anti Sp1 H-
225 sc-14027 (Santa Cruz) and anti-ARP1/COUP-TFII (Santa
Cruz). A complete list of oligonucleotide sequences used as probes
for EMSA is presented in the supplementary materials (Table S1).
RT-PCR
Total RNA was purified from cell lysates using Trizol reagent
(Invitrogen). 2 mg of total RNA was used for reverse transcription
using Anchored Oligo-(dT)23 (Sigma) as primer for 1st strand
synthesis using the RT-AMV kit (Roche). 1:100 dilutions of cDNA
were used as template for quantitative PCR using iQ-SYBR Green
Master Mix (Biorad) in a Biorad Opticon 2 cycler. Q-RT-PCR
values were normalized to ACTB mRNA levels for all samples.
Primer pairs for RT-PCR of ACTB, PCNA, TFF1, MYC, STC2,
and DCC1 are listed in the supplementary materials (Table S1).
Western Blotting
Cell lysates in 1% SDS lysis buffer were quantified using the
Micro BCA Protein Assay Kit (Pierce), and 30 mg of total protein
per well was separated by SDS-PAGE, transferred to PVDF
membranes, and probed with antibodies against ACTIN (Sigma
#A4700, used at 1:500 dilution) or PCNA (Cell Signaling #2586,
used at 1:1000 dilution). Secondary Goat anti-mouse IgG antibody
(conjugated with horseradish peroxidase) was incubated at a
dilution of 1:10,000 and blots were developed using Amersham
ECL Plus Western Blotting Detection Reagents (GE Healthcare).
Chromatin Immunopreciptation (ChIP)-PCR
ChIP was performed as previously described [31]. Briefly,
MCF7 Cells were E2-deprived for 3 days (details above) and then
EREs and PCNA Gene Expression
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45 minutes of E2 exposure has been demonstrated to produce
maximal ERa binding to chromatin [72,78]. ,5610
6 cells per
ChIP were cross-linked with 1% formaldehyde for 10 minutes at
37uC then quenched with 125 mM glycine. The cells were washed
with cold PBS and scraped into PBS with protease inhibitors
(Roche). Cell pellets were resuspended in ChIP lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1) and sonicated
(Fisher Sonic Dysmembrinator) to produce sheared chromatin
with average length 500 bp. The sheared chromatin was
submitted to a clarification spin and the supernatant then used
for ChIP or reserved as ‘‘Input.’’ Antibodies used were anti-ERa
(Ab-1, Ab-3, and AB-10 from Lab Vision and MC-20 from Santa
Cruz). Forward and reverse primer sequences used for ChIP-PCR
are listed in the supplementary materials (Table S1).
Luciferase Reporter Assays
Luciferase reporter assays were performed using the Luciferase
Assay System (Promega) according to the manufacturer’s instruc-
tions. Potential regulatory elements were cloned into pGL2-
Promoter (Promega) and transfected into MCF7 cells using the
TransIT-LT1 Transfection Reagent (Mirus). Cotransfection with
a b-galactosidase expressing plasmid (Promega) enabled normal-
ization of transfection efficiency across samples using a b-
galactosidase assay kit (Promega) according to the manufacturer’s
instructions.
Cloning and Mutagenesis
PCR cloning was performed using PCR amplification of genomic
loci from HESC cell genomic DNA which was prepared using the
Genomic DNA Extraction kit (Qiagen) according to the manufac-
turer’s instructions. PCR products were ligated with the reporter
construct pGL2-promoter (at 59-KpnI+39-XhoI sites) for use in
Luciferase Reporter assays (Promega). Mutagenized reporter
constructs were prepared using the Genetailor Site-Directed
Mutagenesis System (Invitrogen) according to the manufacturer’s
instructions. All clones and subclones were confirmed by DNA
sequencing. Primers used for genomic locus amplification and for
subcloning are listed in the supplementary materials (Table S1).
Statistics
Comparisons between two groups were made using a two-tailed
Student’s t-test with P values indicated.
Supporting Information
Table S1 Table of oligonucleotide primers used for cloning,
mutagenesis, ChIP-PCR, RT-PCR, and EMSA.
Found at: doi:10.1371/journal.pone.0003523.s001 (0.04 MBXLS)
Table S2 Estrogen-responsive transcription factors with predict-
ed binding sites at the 59- and/or 39-promoter regions for the
PCNA gene.
Found at: doi:10.1371/journal.pone.0003523.s002 (0.06 MBXLS)
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